Search ARM

Ankasa Regenerative Therapeutics, Inc. is a clinical stage, venture backed company developing protein therapeutics to enhance bone formation for tissue engineering applications. Ankasa’s lead product, ART352-L, is a liposomal formulation of recombinant human WNT3A protein intended to enhance the osteogenic properties of bone autograft ex vivo through activation of the target genes in the WNT pathway prior to reimplantation in orthopedic reconstructive surgery.

Contact Ankasa Regenerative Therapeutics
Visit Website